IOL Chemicals and Pharmaceuticals Share Price Today (IOLCP)
TODAY IN ONE LINE
IOLCP fell 1.6% on light volume, in line with Nifty's -0.9% move, supported by recent strong earnings.
With a market cap of ₹4,366.22 Cr., it trades at a P/E of 32.20. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
IOL Chemicals and Pharmaceuticals flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 69.7% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 17.4% and Profit up 69.2%
- ●High Promoter HoldingPromoters hold 57.5% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Capital ReturnsLow ROE of 8.4%
Latest IOL Chemicals and Pharmaceuticals News
What changed recently?
Recent events, corporate actions, and announcements.
IOL Chemicals and Pharmaceuticals Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for IOL Chemicals and Pharmaceuticals Limited, framed against the sector median so the premium or discount is obvious at a glance.
IOL Chemicals and Pharmaceuticals Limited trades at a P/E of 32.20× and P/B of 2.46×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
IOL Chemicals and Pharmaceuticals Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for IOL Chemicals and Pharmaceuticals Limited — derived from the live tape, not yesterday's close.
IOL Chemicals and Pharmaceuticals Limited last traded at ₹148.52 with an intraday range of ₹146.58–₹152.64 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹148.52| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 164.03 | +15.51 | +10.45% |
| R3 | 157.97 | +9.45 | +6.37% |
| R2 | 155.31 | +6.79 | +4.57% |
| R1 | 151.91 | +3.39 | +2.28% |
| PIVOT | 149.25 | 0.73 | 0.49% |
| CURRENT | 148.52 | — | — |
| S1 | 145.85 | -2.67 | -1.80% |
| S2 | 143.19 | -5.33 | -3.59% |
| S3 | 139.79 | -8.73 | -5.88% |
| S4 | 133.73 | -14.79 | -9.96% |
IOLCP is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹149.1–₹152.64
Trading Below opening range, showing Bearishness
IOL Chemicals and Pharmaceuticals Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for IOL Chemicals and Pharmaceuticals Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
IOL Chemicals and Pharmaceuticals Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹4,366.22 Cr. and reported EPS of ₹4.69.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 2,079 | 2,319 ▲ 11.5% |
| Sales Growth YoY %Derived | -2.51% | 11.54% |
| Other Income | 22 | 21 ▼ 4.6% |
| Total Income | 2,102 | 2,340 ▲ 11.4% |
| 1,392 | 1,487 ▲ 6.8% | |
| Gross ProfitDerived | 687 | 832 ▲ 21.0% |
| Gross Margin %Derived | 33.06% | 35.87% |
| 485 | 563 ▲ 16.1% | |
| EBITDA (Operating Profit)Derived | 202 | 269 ▲ 33.0% |
| OPM %Derived | 9.73% | 11.60% |
| 87 | 84 ▼ 3.7% | |
| Profit Before Tax (PBT) | 138 | 184 ▲ 33.6% |
| 37 | 47 ▲ 26.6% | |
| Effective Tax %Derived | 26.74% | 25.34% |
| Total Profit for Period | 101 | 138 ▲ 36.2% |
| Net Profit (Owner's PAT)Derived | 101 | 138 ▲ 36.2% |
| Net Profit Margin %Derived | 4.86% | 5.94% |
| PAT Growth YoY %Derived | -24.82% | 36.18% |
| Earnings Per Share (EPS ₹) | 3.44 | 4.69 ▲ 36.3% |
| Diluted Shares Outstanding (Cr) | 29 | 29 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -1 | 3 ▲ 280.6% |
| Total Expenses (incl. D&A & Interest) | 1,964 | 2,156 ▲ 9.8% |
| Material Cost % of RevenueDerived | 65.33% | 64.75% |
| Employee Cost % of RevenueDerived | 10.42% | 10.71% |
| Other Cost % of RevenueDerived | 12.91% | 13.57% |
| Interest Coverage (x)Derived | 8.83x | 12.97x |
| Period | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|
| Revenue from Operations | 2,184 | 2,217 ▲ 1.5% | 2,133 ▼ 3.8% | 2,079 ▼ 2.5% | 2,319 ▲ 11.5% | |
| Sales Growth YoY %Derived | — | 1.52% | -3.80% | -2.51% | 11.54% | |
| Other Income | 32 | 26 ▼ 20.1% | 30 ▲ 17.4% | 22 ▼ 25.5% | 21 ▼ 4.6% | |
| Total Income | 2,216 | 2,243 ▲ 1.2% | 2,163 ▼ 3.6% | 2,102 ▼ 2.8% | 2,340 ▲ 11.4% | |
1,571 | 1,547 ▼ 1.5% | 1,397 ▼ 9.7% | 1,392 ▼ 0.4% | 1,487 ▲ 6.8% | ||
| Gross ProfitDerived | 614 | 670 ▲ 9.2% | 736 ▲ 9.8% | 687 ▼ 6.6% | 832 ▲ 21.0% | |
| Gross Margin %Derived | 28.09% | 30.22% | 34.50% | 33.06% | 35.87% | |
355 | 444 ▲ 25.1% | 505 ▲ 13.7% | 485 ▼ 4.0% | 563 ▲ 16.1% | ||
| EBITDA (Operating Profit)Derived | 258 | 226 ▼ 12.6% | 231 ▲ 2.2% | 202 ▼ 12.3% | 269 ▲ 33.0% | |
| OPM %Derived | 11.83% | 10.18% | 10.81% | 9.73% | 11.60% | |
38 | 63 ▲ 66.5% | 79 ▲ 26.2% | 87 ▲ 9.8% | 84 ▼ 3.7% | ||
| Profit Before Tax (PBT) | 225 | 189 ▼ 16.1% | 182 ▼ 3.7% | 138 ▼ 24.1% | 184 ▲ 33.6% | |
57 | 50 ▼ 13.4% | 47 ▼ 4.6% | 37 ▼ 21.9% | 47 ▲ 26.6% | ||
| Effective Tax %Derived | 25.43% | 26.24% | 26.00% | 26.74% | 25.34% | |
| Total Profit for Period | 168 | 139 ▼ 17.0% | 134 ▼ 3.4% | 101 ▼ 24.8% | 138 ▲ 36.2% | |
| Net Profit (Owner's PAT)Derived | 168 | 139 ▼ 17.0% | 134 ▼ 3.4% | 101 ▼ 24.8% | 138 ▲ 36.2% | |
| Net Profit Margin %Derived | 7.68% | 6.28% | 6.30% | 4.86% | 5.94% | |
| PAT Growth YoY %Derived | — | -17.02% | -3.39% | -24.82% | 36.18% | |
| Earnings Per Share (EPS ₹) | 5.71 | 4.74 ▼ 17.0% | 4.58 ▼ 3.4% | 3.44 ▼ 24.9% | 4.69 ▲ 36.3% | |
| Diluted Shares Outstanding (Cr) | 29 | 29 ▲ 0.0% | 29 ▲ 0.0% | 29 ▲ 0.0% | 29 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -1 | -0 ▲ 66.7% | -1 ▼ 545.0% | -1 ▼ 11.6% | 3 ▲ 280.6% | |
| Total Expenses (incl. D&A & Interest) | 1,991 | 2,054 ▲ 3.2% | 1,981 ▼ 3.5% | 1,964 ▼ 0.9% | 2,156 ▲ 9.8% | |
| Material Cost % of RevenueDerived | 72.29% | 69.28% | 67.29% | 65.33% | 64.75% | |
| Employee Cost % of RevenueDerived | 6.47% | 7.59% | 9.43% | 10.42% | 10.71% | |
| Other Cost % of RevenueDerived | 9.79% | 12.45% | 14.26% | 12.91% | 13.57% | |
| Interest Coverage (x)Derived | 25.94x | 10.90x | 10.41x | 8.83x | 12.97x |
IOL Chemicals and Pharmaceuticals segment analysis : revenue and profit mix.
Disclosed business segments at IOL Chemicals and Pharmaceuticals with their share of revenue and profit, switchable between consolidated and standalone reporting.
IOL Chemicals and Pharmaceuticals discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for IOL Chemicals and Pharmaceuticals Limited.
Our AI distills the core fundamental drivers supporting IOL Chemicals and Pharmaceuticals Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
IOL Chemicals and Pharmaceuticals Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Strong promoter holding 57.48% ensures aligned long-term strategic vision.
Latest quarterly EPS grew 69.2% YoY despite competitive pressures.
TTM revenue growth 17.4% outpaces peer average, signaling market traction.
Low debt-to-equity ratio 0.0008 provides substantial financial flexibility.
Operating cash flow consistently positive, exceeds net profit quality.
Key Risks.
Operating margin 11.60% significantly lags peer average 16–33%.
ROE 8.38% and ROCE 11.20% trail peer benchmarks substantially.
P/E 31.30x elevated, limiting valuation appeal despite growth.
Dividend yield 0.59% modest, limiting income-focused investor appeal.
FII holdings eased from 3.54% to 1.47%, signals foreign investor caution.
Flip Conditions.
Valuation risk. a P/E above 42 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.32%.
IOL Chemicals and Pharmaceuticals Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — IOL Chemicals and Pharmaceuticals Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
IOL Chemicals and Pharmaceuticals Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for IOL Chemicals and Pharmaceuticals Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
IOL Chemicals and Pharmaceuticals Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for IOL Chemicals and Pharmaceuticals Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in IOL Chemicals and Pharmaceuticals Limited stood at 36.0% of traded volume, against a 20-day average of 31.6%.
IOL Chemicals and Pharmaceuticals announcements: results, concalls, ratings, M&A.
Filings IOL Chemicals and Pharmaceuticals sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
IOL Chemicals and Pharmaceuticals files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 92 documents below.
General Updates
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about General Updates
Certificate under SEBI (Depositories and Participants) Regulations, 2018
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Credit Rating
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Credit Rating
Trading Window
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider…
Copy of Newspaper Publication
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
Investor decks & rating reports.
IOL Chemicals and Pharmaceuticals dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue IOL Chemicals and Pharmaceuticals has declared, sequenced by announce and record date.
IOL Chemicals and Pharmaceuticals corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
IOL Chemicals and Pharmaceuticals insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in IOL Chemicals and Pharmaceuticals as reported to SEBI — buying and selling signals from the people who know the business best.
IOL Chemicals and Pharmaceuticals insider activity below tracks 20 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| NCVI Enterprises Limited | Insider | 19 Mar 2026 | buy | +4.04 L | ₹3.01 Cr. | ₹74.56 |
| NCVI Enterprises Limited | Insider | 19 Mar 2026 | buy | +4.04 L | ₹3.01 Cr. | ₹74.56 |
| NCVI Enterprises Limited | Insider | 19 Mar 2026 | buy | +4.04 L | ₹3.01 Cr. | ₹74.56 |
| NCVI Enterprises Limited | Insider | 19 Mar 2026 | buy | +4.04 L | ₹3.01 Cr. | ₹74.56 |
| NCVI Enterprises Limited | Insider | 18 Mar 2026 | buy | +7.00 L | ₹5.14 Cr. | ₹73.44 |
| Mayadevi Polycot Limited | Insider | 18 Mar 2026 | buy | +54.2 K | ₹40 L | ₹73.81 |
| NCVI Enterprises Limited | Insider | 18 Mar 2026 | buy | +7.00 L | ₹5.14 Cr. | ₹73.44 |
| Mayadevi Polycot Limited | Insider | 18 Mar 2026 | buy | +54.2 K | ₹40 L | ₹73.81 |
| NCVI Enterprises Limited | Insider | 18 Mar 2026 | buy | +7.00 L | ₹5.14 Cr. | ₹73.44 |
| Mayadevi Polycot Limited | Insider | 18 Mar 2026 | buy | +54.2 K | ₹40 L | ₹73.81 |
About IOL Chemicals and Pharmaceuticals Limited: business, sector, key facts.
What IOL Chemicals and Pharmaceuticals Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
IOL Chemicals and Pharmaceuticals Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: IOLCP, BSE: 524164.
IOL Chemicals and Pharmaceuticals Limited (IOLCP) is a prominent Indian company engaged in the manufacturing and sale of pharmaceutical and chemical products both domestically and globally. Their core business revolves around the production and distribution of a wide range of Active Pharmaceutical Ingredients (APIs).
A significant portion of IOLCP's API portfolio focuses on ingredients used in various therapeutic areas. This includes APIs for anti-inflammatory, analgesic and antipyretic treatments (like ibuprofen lysinate and ibuprofen sodium), anti-diabetic medications (metformin), anti-platelet agents (clopidogrel bisulphate), cholesterol-lowering drugs (fenofibrate), anti-convulsants (lamotrigine, gabapentin, levetiracetam), and proton pump inhibitors (pantoprazole). The company also produces paracetamol, a common analgesic and antipyretic.
Beyond pharmaceuticals, IOLCP demonstrates a strong presence in the specialty industrial chemicals market. They supply a diverse array of products including ethyl acetate, isobutyl benzene, acetyl chloride, para-aminophenol, and monochloroacetic acid. These chemicals find applications across a wide spectrum of industries, such as food processing, flexible packaging, pharmaceuticals, textiles, ink and paint manufacturing, pesticide production, and the creation of chemical intermediates. This diversification allows IOLCP to cater to multiple sectors and reduces reliance on any single market.
Established in 1986 and headquartered in Ludhiana, India, IOLCP has a long history of operation within the chemical and pharmaceutical sectors. Their success is built on the foundation of providing high-quality APIs and specialty chemicals, contributing significantly to various industries both within India and internationally. The company's broad product range and diversified customer base solidify its position as a key player in the market.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about IOL Chemicals and Pharmaceuticals Limited (IOLCP).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of IOL Chemicals and Pharmaceuticals Limited (IOLCP)?
The current share price of IOL Chemicals and Pharmaceuticals Limited (IOLCP) is ₹148.52. Today, the stock has declined by ₹2.48 (1.64%), trading in a range of ₹146.58 to ₹152.64. The stock opened at ₹151 with a trading volume of 12,73,482 shares.
02Is IOL Chemicals and Pharmaceuticals Limited stock a good investment for long-term?
IOL Chemicals and Pharmaceuticals Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹4,366.22 crores, P/E ratio of 32.20, ROE of 8.38%, and ROCE of 11.20%. The dividend yield stands at 0.64%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of IOL Chemicals and Pharmaceuticals Limited stock?
The 52-week high price of IOL Chemicals and Pharmaceuticals Limited (IOLCP) is ₹179.6, while the 52-week low is ₹67.19. Currently trading at ₹148.52, the stock is 72.4% away from its 52-week low and 17.3% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy IOL Chemicals and Pharmaceuticals Limited stock at the current price?
Whether to buy IOL Chemicals and Pharmaceuticals Limited stock at ₹148.52 depends on multiple factors. The stock is currently trading with a P/E ratio of 32.20 and P/B ratio of 2.46. Today's performance shows a loss of 1.64%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of IOL Chemicals and Pharmaceuticals Limited and when is the next dividend?
IOL Chemicals and Pharmaceuticals Limited offers a dividend yield of 0.64%, which means for every ₹100 invested at the current price of ₹148.52, you can expect to receive approximately ₹0.64 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of IOL Chemicals and Pharmaceuticals Limited?
IOL Chemicals and Pharmaceuticals Limited's key financial metrics include: P/E Ratio: 32.20, P/B Ratio: 2.46, ROE: 8.38%, ROCE: 11.20%, Dividend Yield: 0.64%, EPS: ₹4.69, Book Value: ₹61.24, and Debt-to-Equity: 0.08. The company's market cap stands at ₹4,366.22 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is IOL Chemicals and Pharmaceuticals Limited stock performing today in the market?
IOL Chemicals and Pharmaceuticals Limited stock opened at ₹151 and is currently trading at ₹148.52, showing a decline of ₹2.48 (1.64%). The intraday high is ₹152.64 and low is ₹146.58. The trading volume stands at 12,73,482 shares, indicating strong market participation today.
08What is the P/E ratio of IOL Chemicals and Pharmaceuticals Limited and what does it indicate?
IOL Chemicals and Pharmaceuticals Limited has a Price-to-Earnings (P/E) ratio of 32.20, which means investors are willing to pay ₹32.20 for every ₹1 of earnings. With an EPS of ₹4.69, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about IOL Chemicals and Pharmaceuticals Limited (IOLCP) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.